The Efforts to Prevent Cancer Genetic Testing are Coming to an End
Annals of Surgical Oncology –
Related Articles
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL
On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with bendamustine and rituximab…
World Cancer Day 2025: International Journal of Cancer
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Trump orders US to leave World Health Organization
Trump has long been critical of how the Geneva-based institution handled the Covid-19 pandemic.
Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.
Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma
Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.
Call-for-Papers | JACC: CardioOncology
Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.
NewsDetails
Rachel Darwin, Senior Manager, Public Relations Free information from the National Comprehensive Cancer Network offers information on how and why to access genetic counseling and…
Upcoming Insights – Strategies for Management of Dermatological Reactions from Combination Amivantamab/ Lazertinib for EGFR-mutated NSCLC
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
